Exiting opportunity for QC Scientist with ICP-MS experience in Oncoinvent ASA!

Oncoinvent ASA is looking for a Scientist in the Quality Control department at the company manufacturing facility in Oslo. The position is an exciting opportunity to work in an innovative and dynamic start-up company and participate in the production of novel pharmaceuticals. What we are looking for is an individual enjoying working hands-on in the lab and has experience with ICP-MS and method development. The successful candidate will, together with the Quality Control team, be responsible for quality control of raw materials, drug substance (Ra-224) and drug product (Radspherin®). This position requires work with radioactive materials. A successful candidate is therefore expected to comply with radiation protection and other health and safety procedures during laboratory- and production scale experiments, and GMP production activities. Key responsibilities

• Conduct chemical and physical release testing of raw materials, intermediates and finished product. Being hands-on on various types of tasks.
• Develop analytical methods for testing of raw materials, intermediates and finished product.
• Participate in the validation of these test methods.
• Investigate deviations and closing of the records in a timely fashion.
• Resolve, in collaboration with the QC, QA and production team, out-of-specification or unexpected results and analytical- and product problems.
• Maintain and troubleshoot analytical instrumentation as needed. Performing audits on equipment periodically to verify proper calibration and use.
• Record and report result of analysis in accordance with prescribed lab procedures and systems.
• Writing of SOPs and other instructional documents.
• Procurement and qualification of analytical instruments.
• Perform environmental monitoring.

Qualifications and experienceThe holder of the QC Scientist position should have the following documented qualifications and experience:

• Bachelor or master level within analytical chemistry or equivalent. Candidates with previous relevant experience are desirable, but recent graduates are also welcome to apply.
• Experience with ICP-MS.
• Experience with method development and method validation.
• Knowledge of Good Manufacturing Practice (GMP).
• Good language skills, written and spoken, in both Norwegian and English
• To be successful in the role, it is also important to have the following personal qualities:
• Ability to work in a structured and independent manner
• Conscious of responsibility
• Good ability to implement and adapt
• Good communication skills and good at interacting with others
• Solution-oriented
• Strong problem-solving and troubleshooting skills.
• Ownership of own and others' deliveries towards common goals

Location and working hoursThe holder of this position will be based at Oncoinvent ASA, Gullhaugveien 7, 0484 Oslo. The position will report to the Head of Quality Control. The main part of the work will take place during normal working hours, but evening work and work on national holidays might occasionally be necessary for quality control of intermediate and final products. Application deadline: We are reviewing candidates on a rolling basis.
Please submit your application with a motivational letter stating “why Oncoinvent” and what you can contribute to the position as well as an updated CV. Application without this will not be reviewed further.

Oncoinvent is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The lead product candidate, Radspherin, uses the alpha-emitting radionuclide radium-224, directly targeting micro-metastases post-surgery, harnessing the benefits of modern radiopharmaceuticals without the complexities of biological targeting. Oncoinvent is investigating the safety and efficacy of Radspherin in a clinical development program in two indications. Currently two phase 1/2a trials and one randomized phase 2 trial are ongoing in the US, UK and Europe. More than 150 patients with peritoneal carcinomatosis, secondary to ovarian and colorectal cancer, will be enrolled in the current program. Preliminary clinical efficacy data are highly encouraging, and no serious toxicity or safety concerns have been reported to date. The Oncoinvent team consists of approx. 30 employees and runs a state-of-the-art manufacturing facility to produce drug products for clinical trials in Nydalen, Oslo. Oncoinvent is listed on the Euronext Growth Oslo (ONCIN:OL).